Brexpiprazole
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To review the pharmacology and clinical data for brexpiprazole in schizophrenia and major depressive disorder (MDD). DATA SOURCES: An English-language literature search using PubMed and MEDLINE was performed using the term brexpiprazole. All articles containing human clinical trial data published up to September 2016 were evaluated for inclusion as well as information from the manufacturer's product labeling. STUDY SELECTION/DATA EXTRACTION: Phase 3 trials for brexpiprazole were evaluated. Key in vitro and animal data were incorporated into the pharmacology and pharmacokinetic sections where appropriate. DATA SYNTHESIS: Four phase 3 trials have evaluated the use of brexpiprazole as a primary therapy for schizophrenia or as an antidepressant adjunct for MDD. For its schizophrenia indication, brexpiprazole was studied in 2 placebo-controlled trials of approximately 1300 patients, with 4 mg of brexpiprazole consistently showing superiority over placebo. For MDD, brexpiprazole was compared with placebo as an adjunct to antidepressants in approximately 1000 patients who had failed trials of 1 to 3 prior antidepressants. The 2-mg and 3-mg dosages of brexpiprazole showed consistent superiority over placebo in the MDD trials. Common treatment emergent adverse effects included akathisia and weight gain. CONCLUSIONS: Brexpiprazole showed efficacy for the treatment of schizophrenia in the range of 2 to 4 mg/d and as an adjunct to antidepressant therapy in MDD when dosed at 2 to 3 mg/d. Advantages of this drug include once-daily dosing, good tolerability, and lack of effect on sexual function. Disadvantages include the lack of long-term safety data and potentially high cost.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“Thus, at this time, the evidence does not justify any distinct advantage of using brexpiprazole first-line over the less-costly agent aripiprazole, which is also a partial agonist at D 2 and 5HT 1A receptors, with low risk of metabolic adverse effects and hyperprolactinemia.(23)”
BackgroundDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372 · cited 2×
“Preliminary data suggest that inhibition of norepinephrine α 1B receptors may contribute to brexpiprazole’s antipsychotic effect, whereas it has been suggested that norepinephrine α 2C antagonism may play a role in antidepressant and procognitive effects.(7) Pharmacokinetics”
BackgroundKane, J. M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.038 · Cited by 325
Correll, C. U., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101275 · Cited by 183
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182 · cited 9×
“4%).(12) The other phase 3 trial also assessed the efficacy, safety, and tolerability of brexpiprazole adjunctive to ADTs at doses of 1 and 3 mg.”
BackgroundMethodResultInfluentialThase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Born to Be Criminal? What to Make of Early Biological Risk Factors for Criminal Behavior
Sterzer, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09111601 · Cited by 133
Duru, G., & Fantino, B. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x291958 · Cited by 112
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63 · cited 2×
“Previous studies have indicated that 5-HT 2A antagonism plays a role in the mitigation of dopamine-related side effects such as extrapyramidal effects (EPS).(6,9) Preliminary data suggest that inhibition of norepinephrine α 1B receptors may contribute to brexpiprazole’s antipsychotic effect, whereas it has been sugges…”
BackgroundOosterhof, C. A., Mansari, M. E., & Blier, P. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218578 · Cited by 50
Yoshimi, N., Fujita, Y., Ohgi, Y., Futamura, T., Kikuchi, T., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.06.008 · Cited by 46
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
Sussman, M., Yu, J., Kamat, S., Hartry, A., Legacy, S. N., Duffy, R. A., & Aigbogun, M. S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.006 · Cited by 11
Research works printed but not linked: 3
- Lehman AF, 2004, Am J Psychiatry, 161, 1
- Nelson C, 2015, Poster presented at: 168th American Psychiatric Association Annual Meeting
- Correll CU, 2015, Poster presented at: 15th International Congress on Schizophrenia Research (ICOSR)
Cited by
Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders
Grinchii, D., & Dremencov, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249532 · Cited by 160
“In particular, creditable effectiveness as adjuncts to antidepressant drugs in treatment-resistant depression was demonstrated for aripiprazole [21], brexpiprazole [22], and risperidone [23].”
BackgroundRegulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
Madireddy, S., & Madireddy, S. (2020) · Brain Sciences · doi:10.3390/brainsci10100742 · Cited by 61
Demyttenaere, K., Detraux, J., Racagni, G., & Vansteelandt, K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00625-3 · Cited by 56
Qiao, Y., Zhou, J., Liang, J., Deng, X., Zhang, Z., Huang, H., Li, S., Dai, S.-F., Liu, C., Luan, Z., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153436 · Cited by 34
Pesantez, G. S. P., & Clayton, A. H. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200039 · Cited by 19
Metadata
- Authors
- Markovic, M., Gallipani, A., Patel, K. H., & Maroney, M.
- Affiliations
- Rutgers, The State University of New Jersey, Piscataway Township, NJ, USA
- Brooklyn Hospital Center (US)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Maroney, Megan
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2016-12-15
- Volume
- 51
- Issue
- 4
- Pages
- 315-322
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2575166050
- Semantic Scholar
- 5e15f02ea810b329f5b86907564b5e4e1709d2db
- Cited by
- 22
- References
- 15
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- brexpiprazole, schizophrenia, major depressive disorder, atypical antipsychotics, pharmacokinetics, akathisia, weight gain, treatment-emergent adverse events, drug efficacy, sexual function
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Drug Therapy, Combination, Humans, Schizophrenia, Thiophenes, Antipsychotic Agents, Quinolones, Weight Gain, Clinical Trials, Phase III as Topic, Receptors, Dopamine D2, Receptor, Serotonin, 5-HT1A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.